# The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia

> **NCT02844322** · PHASE4 · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 35 (actual)

## Conditions studied

- Waldenström Macroglobulinemia

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT02844322
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2022-05
- **Final completion:** 2023-05
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02844322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02844322, "The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02844322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*